Acute	acute	O	O	O	O
bronchodilating	bronchodilating	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
ipratropium	ipratropium	O	O	OTHERS	I
bromide	bromide	O	O	OTHERS	I
and	and	O	O	O	O
theophylline	theophylline	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
chronic	chronic	O	O	OTHERS	I
obstructive	obstructive	O	O	OTHERS	I
pulmonary	pulmonary	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
bronchodilator	bronchodilator	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
ipratropium	ipratropium	O	O	OTHERS	I
bromide	bromide	O	O	OTHERS	I
aerosol	aerosol	O	O	O	O
(	(	O	O	O	O
36	36	O	O	O	O
micrograms	micrograms	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
short-acting	short-acting	O	O	O	O
theophylline	theophylline	CHEMICALS	O	OTHERS	I
tablets	tablets	O	O	O	O
(	(	O	O	O	O
dose	dose	O	O	O	O
titrated	titrated	O	O	O	O
to	to	O	O	O	O
produce	produce	O	O	O	O
serum	serum	O	O	O	O
levels	levels	O	O	O	O
of	of	O	O	O	O
10	10	O	O	O	O
-	-	O	O	O	O
20	20	O	O	O	O
micrograms/mL	micrograms/ml	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
double-blind	double-blind	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
crossover	crossover	O	O	O	O
study	study	O	O	O	O
in	in	O	O	O	O
21	21	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
stable	stable	O	O	O	O
,	,	O	O	O	O
chronic	chronic	O	O	OTHERS	I
obstructive	obstructive	O	O	OTHERS	I
pulmonary	pulmonary	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
.	.	O	O	O	O

Mean	mean	O	O	O	O
peak	peak	O	O	O	O
forced	forced	O	O	O	O
expiratory	expiratory	O	O	O	O
volume	volume	O	O	O	O
in	in	O	O	O	O
1	1	O	O	O	O
second	second	O	O	O	O
(	(	O	O	O	O
FEV1	fev1	O	O	O	O
)	)	O	O	O	O
increases	increases	O	O	O	O
over	over	O	O	O	O
baseline	baseline	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
proportion	proportion	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
attaining	attaining	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
a	a	O	O	O	O
15	15	O	O	O	O
%	%	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
FEV1	fev1	O	O	O	O
(	(	O	O	O	O
responders	responders	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
31	31	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
90	90	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
for	for	O	O	O	O
ipratropium	ipratropium	O	O	OTHERS	I
and	and	O	O	O	O
17	17	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
50	50	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
for	for	O	O	O	O
theophylline	theophylline	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
average	average	O	O	O	O
FEV1	fev1	O	O	O	O
increases	increases	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
6-hour	6-hour	O	O	O	O
observation	observation	O	O	O	O
period	period	O	O	O	O
were	were	O	O	O	O
18	18	O	O	O	O
%	%	O	O	O	O
for	for	O	O	O	O
ipratropium	ipratropium	O	O	OTHERS	I
and	and	O	O	O	O
8	8	O	O	O	O
%	%	O	O	O	O
for	for	O	O	O	O
theophylline	theophylline	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
mean	mean	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
action	action	O	O	O	O
was	was	O	O	O	O
3.8	3.8	O	O	O	O
hours	hours	O	O	O	O
with	with	O	O	O	O
ipratropium	ipratropium	O	O	OTHERS	I
and	and	O	O	O	O
2.4	2.4	O	O	O	O
hours	hours	O	O	O	O
with	with	O	O	O	O
theophylline	theophylline	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

While	while	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
were	were	O	O	O	O
rare	rare	O	O	O	O
,	,	O	O	O	O
those	those	O	O	O	O
experienced	experienced	O	O	O	O
after	after	O	O	O	O
theophylline	theophylline	CHEMICALS	O	OTHERS	I
use	use	O	O	O	O
did	did	O	O	O	O
involve	involve	O	O	O	O
the	the	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
and	and	O	O	O	O
gastrointestinal	gastrointestinal	O	O	O	O
systems	systems	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
show	show	O	O	O	O
that	that	O	O	O	O
ipratropium	ipratropium	O	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
more	more	O	O	O	O
potent	potent	O	O	O	O
bronchodilator	bronchodilator	O	O	O	O
than	than	O	O	O	O
oral	oral	O	O	O	O
theophylline	theophylline	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
chronic	chronic	O	O	OTHERS	I
airflow	airflow	O	O	OTHERS	I
obstruction	obstruction	O	O	OTHERS	I
.	.	O	O	O	O

